Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. The founding team includes scientists who have led the advancement of gene therapy over the past two decades, establishing human proof of concept of the expression of gene therapy in the eye and liver. Spark’s robust pipeline includes SPK-RPE65, a fully enrolled, pivotal Phase 3 program in blindness due to mutations in the RPE65 gene, SPK-CHM for the treatment of choroideremia, and SPK-FIX, a program for the potential treatment of hemophilia B through a global collaboration with Pfizer Inc., as well as preclinical programs to address neurodegenerative diseases and other retinal degenerative diseases and hematologic disorders. Spark has rights to a proprietary manufacturing platform that has a track record supporting clinical studies across diverse therapeutic areas and routes of administration. Spark’s expertise across research, clinical, regulatory and manufacturing builds on a legacy of innovation and excellence in gene therapy established by Spark’s team while at The Children’s Hospital of Philadelphia Center for Cellular and Molecular Therapeutics.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
Frequently Asked Questions
What is Market Cap of Spark Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Spark Therapeutics Inc market cap is N/A.
What is the 52-week high for Spark Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Spark Therapeutics Inc 52 week high is N/A as of April 29, 2024.
What is the 52-week low for Spark Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Spark Therapeutics Inc 52 week low is N/A as of April 29, 2024.
What was Spark Therapeutics Inc stock price yesterday?
Spark Therapeutics Inc stock price yesterday was $113.57.
What is the PE ratio of Spark Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Spark Therapeutics Inc’s P/E ratio is None.
What is the Price-to-Book ratio of Spark Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Spark Therapeutics Inc P/B ratio is None.
What is Spark Therapeutics Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Spark Therapeutics Inc's EBITDA is -14.58.
What is the 50-day moving average of Spark Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Spark Therapeutics Inc 50-day moving average is N/A.
How many employess does Spark Therapeutics Inc has?